-
Mashup Score: 4First patient dosed in a Phase 1 ALS study testing AMX0114 - 10 day(s) ago
AMX0114 is an antisense oligonucleotide made to prevent or slow the degeneration of axons, which is a key driver of ALS progression.
Source: alsnewstoday.comCategories: General Medicine NewsTweet
-
Mashup Score: 4Focus of NORD study: Rare disease community's lived experiences - 21 day(s) ago
NORD has launched a U.S. study called Living Rare to capture the lived experiences of rare disease patients and identify changing unmet needs.
Source: alsnewstoday.comCategories: General Medicine NewsTweet-
Living Rare Study News Alert! Read in @alsnewstoday how NORD’s #LivingRareStudy is making sure #RareDisease patients and caregivers are heard – and transforming real-world experiences into powerful data: https://t.co/cWBW4DJfyo Join the Living Rare Study today! #ALS
-
-
Mashup Score: 0Study: Repeated brain injury speeds up ALS onset and progression... - 3 month(s) ago
Repeated brain injury resulted in SOD1-ALS mice showing greater weight loss, an earlier tremor in the hind limbs, and shortened survival.
Source: alsnewstoday.comCategories: General Medicine News, Rare DiseaseTweet-
Unlucky rodents... Repeated brain injury resulted in SOD1-ALS mice showing greater weight loss, an earlier tremor in the hind limbs, and shortened survival. https://t.co/TNHI1hWJtH
-
-
Mashup Score: 3First ALS patient dosed in Phase 1 trial testing Quralis' QRL-101 - 5 month(s) ago
The first ALS patient was dosed in a Phase 1 trial of Quralis’ first-in-class therapy QRL-101, which is still enrolling at a site in Europe.
Source: alsnewstoday.comCategories: General Medicine News, Rare DiseaseTweet-
The first ALS patient was dosed in a Phase 1 trial of Quralis' first-in-class therapy QRL-101, which is still enrolling at a site in Europe. https://t.co/ZbhG1MoB7R
-
-
Mashup Score: 0Auttx gets ALS Network grant to develop new treatments for ALS - 6 month(s) ago
Auttx has received a grant from the ALS Network to advance research on treatments for ALS that could restore normal RNA processing functions.
Source: alsnewstoday.comCategories: General Medicine News, Rare DiseaseTweet-
Auttx has received a grant from the ALS Network to advance research on treatments for ALS that could restore normal RNA processing functions. https://t.co/5clJaeUFxX
-
-
Mashup Score: 0Avicenna gets patent for ROCK inhibitor compounds for ALS, more - 6 month(s) ago
Avicenna received a patent covering ROCK inhibitor compounds for ALS, Parkinson’s, and other neurodegenerative conditions.
Source: alsnewstoday.comCategories: General Medicine News, Rare DiseaseTweet-
Avicenna received a patent covering ROCK inhibitor compounds for ALS, Parkinson’s, and other neurodegenerative conditions. https://t.co/jLQWtT2iEX
-
-
Mashup Score: 4RNS60 aids mitochondria health, protects motor neurons in ALS mice - 7 month(s) ago
RNS60 is an experimental therapy designed to boost the formation of new mitochondria and restore energy production in nerve cells.
Source: alsnewstoday.comCategories: General Medicine News, Rare DiseaseTweet-
Lucky rodents. RNS60 is an experimental therapy designed to boost the formation of new mitochondria and restore energy production in nerve cells. https://t.co/kHMTjgrPMM
-
-
Mashup Score: 0Mabylon receives funding to advance TDP-43 intrabodies for ALS - 7 month(s) ago
Mabylon has received grants from Target ALS and the ALS Association to develop human-derived antibodies to help restore TDP-43 in patients.
Source: alsnewstoday.comCategories: General Medicine News, Rare DiseaseTweet-
Mabylon has received grants from Target ALS and the ALS Association to develop human-derived antibodies to help restore TDP-43 in patients. https://t.co/sOWbiLhlXQ
-
-
Mashup Score: 7Clene submits new CNM-Au8 efficacy data head of FDA meeting - 8 month(s) ago
Clene submitted new data on CNM-Au8 to the FDA ahead of an upcoming meeting to discuss potential accelerated approval for the ALS therapy.
Source: alsnewstoday.comCategories: General Medicine News, Rare DiseaseTweet-
Clene submitted new data on CNM-Au8 to the FDA ahead of an upcoming meeting to discuss potential accelerated approval for the ALS therapy. https://t.co/1hlJDsrDKa
-
-
Mashup Score: 3Bill targets research on environmental factors and ALS - 8 month(s) ago
Proposed U.S. legislation would advance research on the link between environmental factors and ALS and other neurodegenerative diseases.
Source: alsnewstoday.comCategories: General Medicine News, Rare DiseaseTweet-
Can we please eliminate the expensive duplication of efforts between CDC and NIH??? https://t.co/rl7mXcCdd1
-
Something simple I have learned from a smart ALS advocate -- "Last patient dosed" is a more important milestone. AMX0114 is an antisense oligonucleotide made to prevent or slow the degeneration of axons, which is a key driver of ALS progression. https://t.co/c0iaUj2Fdl